International Conference on the Management of Liver Diseases

Organised by Patrick Marcellin & Laurent Castera – Association for the Promotion of Hepatologic Care (APHC)

OTHER

#P04 - Translating the Role of Vitamin D Supplementation in Chronic Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials

P. MARTINEKOVA¹, M. OBEIDAT¹, M. TOPALA¹, S. VÁNCSA¹, D.S. VERES¹, Á. ZOLCSÁK¹, L. FÖLDVÁRI-NAGY¹, B. ERŐSS¹, P. HEGYI¹, K. HAGYMÁSI¹

(1) Centre for Translational Medicine, Semmelweis University, Budapest - (Hungary)

Background & Aims

Vitamin D (VD) deficiency is highly prevalent in chronic liver disease (CLD). Although international societies recommend supplementation in cases of proven deficiency, its impact on CLD remains uncertain. Our aim was to evaluate the effect of VD supplementation in CLD by conducting a systematic review and meta-analysis of randomized controlled trials.

Methods

We systematically searched three databases on 8th November 2022 (PROSPERO: CRD42022370312). Our outcomes involved survival, controlled attenuation parameter (CAP), liver stiffness measurement (LSM), changes in liver enzymes and homeostasis model assessment of insulin resistance (HOMA-IR), among others. Pooled risk ratio (RR), mean difference (MD), and 95% confidence intervals (CI) were calculated using the random-effects model.

Results


Forty-one RCTs were included, comprising 3,562 patients. When comparing the VD group with the control, the overall survival RR was 1.14 (CI: 0.85; 1.54; 4 RCTs) at 6 months and 0.99 (CI:0.83;1.17; 4 RCTs) at 12 months. VD resulted in non-significant lower CAP (3 RCTs, MD:-23.50 dB/m; CI:-81.72, 34.72) and LSM (3 RCTs, MD:-0.65 kPa; CI: 1.98;0.68). A significant reduction in HOMA-IR was observed in the VD group (12 RCTs; MD: 0.44; CI:-0.87;-0.01). Alanineaminotransferase (20 RCTs; MD:-3.26 IU/L; CI:-6.37,-0.16) and gammaglutamyltransferase (10 RCTs; MD: 5.15 IU/L; CI: 9.05;-1.25) were significantly reduced.

Conclusions

Our results showed significant differences for ALT, GGT, and HOMA-IR in the VD group. In addition, there were no differences in survival, CAP, and LSM. Further RCTs with adequate power are warranted to clarify the results.

Liver steatosis, fibrosis and survival:

https://livebyglevents.key4register.com/key4register/api.aspx?e=199&img=Paris+conference.jpg&ai=10869&op=getabstractimg&dirN=0.



www.aphc-paris.com live! by GL events